CliffBio
biologic

Danyelza

naxitamab-gqgk

Loss of exclusivityNovember 2032projected — 12-year biologic exclusivity estimate
CompanyY-mAbs Therapeutics →See this company's full patent-cliff portfolio

Drug detail

Brand nameDanyelza
Active ingredientnaxitamab-gqgk
Strength40MG/10ML (4MG/ML)
Dosage formInjection
RouteIntravenous
ModalityBiologic
FDA approvalNovember 2020
Marketing statusRx

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.